Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $183.06 USD
Change Today +2.28 / 1.26%
Volume 366.9K
JAZZ On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

jazz pharmaceuticals plc (JAZZ) Snapshot

Open
$181.14
Previous Close
$180.78
Day High
$184.10
Day Low
$180.94
52 Week High
04/27/15 - $191.01
52 Week Low
08/8/14 - $131.69
Market Cap
11.2B
Average Volume 10 Days
469.3K
EPS TTM
$4.89
Shares Outstanding
61.1M
EX-Date
--
P/E TM
37.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for JAZZ PHARMACEUTICALS PLC (JAZZ)

jazz pharmaceuticals plc (JAZZ) Related Businessweek News

No Related Businessweek News Found

jazz pharmaceuticals plc (JAZZ) Details

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate that is in phase I clinical trail for use in patients with narcolepsy. In addition, it develops products in the areas of hematology and oncology, such as JZP-416, which has completed phase I clinical trial for the treatment of patients with ALL who are hypersensitive to E. coli-derived asparaginase; and Leukotac, an anti-CD25 monoclonal antibody that is in phase III clinical trials for the treatment of steroid-refractory acute graft vs. host disease. The company is headquartered in Dublin, Ireland.

835 Employees
Last Reported Date: 05/7/15

jazz pharmaceuticals plc (JAZZ) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: $830.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $402.9K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $493.5K
Executive Vice President and General Counsel
Total Annual Compensation: $483.5K
Senior Vice President of U.S. Commercial
Total Annual Compensation: $296.2K
Compensation as of Fiscal Year 2014.

jazz pharmaceuticals plc (JAZZ) Key Developments

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc. announced results from the recently completed Phase 1 clinical study of JZP-386, a deuterium-containing analog of sodium oxybate. The Phase 1 study evaluated the safety, pharmacokinetics and pharmacodynamics (PD) of JZP-386 in 30 healthy volunteers. Clinical data from this Phase 1 study demonstrated that JZP-386 provided favorable deuterium-related effects, including higher serum concentrations and correspondingly increased PD effects at clinically relevant time points compared to Xyrem® (sodium oxybate) oral solution. The safety profile of JZP-386 was similar to that observed with Xyrem. While the companies have determined that the deuterium-related effects observed in the Phase 1 studies do not support advancing into a later-stage clinical trial of JZP-386 at this time, the results indicate that further evaluation of JZP-386 is warranted. Accordingly, the companies intend to explore formulation options to enhance the positive effects observed in the studies to achieve an improved product profile for patients with narcolepsy. Sodium oxybate is the active ingredient in Xyrem, a prescription medicine marketed in the United States by Jazz Pharmaceuticals to treat cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy, a serious neurological disorder that affects approximately 1 in 2,000 people in the United States.

Jazz Pharmaceuticals Public Limited Company Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for the Full Year of 2015

Jazz Pharmaceuticals Public Limited Company announced consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $309,303,000 compared with $246,919,000 for the same period a year ago. Income from operations was $116,759,000 compared with loss from operations of $66,659,000 for the same period a year ago. Income before income tax provision was $102,759,000 compared with loss before income tax of $76,612,000 for the same period a year ago. Net income attributable to Jazz Pharmaceuticals plc was $70,700,000 or $1.12 per diluted share compared with net loss attributable to Jazz Pharmaceuticals plc $92,650,000 or $1.58 per diluted share for the same period a year ago. Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc was $125,068,000 or $1.99 per diluted share compared with $99,538,000 or $1.59 per diluted share for the same period a year ago. Non-GAAP adjusted income before tax was $154,979,000 compared with $122,778,000 for the same period a year ago. The increase in total Revenue was driven primarily by higher net product sales of Xyrem® (sodium oxybate) oral solution, Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi) and Defitelio® (defibrotide). Total revenues include net product sales, royalties and contract revenues. The company reaffirmed earnings guidance for the full year of 2015. For the full year of 2015, the company expects to report revenues in the range of $1,310 million to $1,370 million, total net product sales in the range of $1,303 million to $1,363 million, Xyrem net sales in the range of $950 million to $970 million, Erwinaze/Erwinase net sales in the range of $200 million to $215 million, Defitelio/defibrotide net sales in the range of $73 million to $83 million, adjusted gross margin in the range of 92% to 93%, adjusted R&D expenses in the range of $95 million to $105 million, adjusted interest expense of $40 million, GAAP net income attributable to Jazz Pharmaceuticals plc per diluted share in the range of $5.17 to $5.70 and non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share in the range of $9.45 to $9.75.

Jazz Pharmaceuticals Seeks Acquisitions

Jazz Pharmaceuticals Public Limited Company (NasdaqGS:JAZZ) is looking for acquisition. Matt Young, Senior Vise President and Chief Financial Officer of Jazz Pharmaceuticals states, "We continue to focus on investing in the growth of our key commercial products, advancing our pipeline, working toward regulatory approval of defibrotide in the US, and pursuing acquisition opportunities to further grow and diversify our product portfolio and pipeline."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JAZZ:US $183.06 USD +2.28

JAZZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $43.84 USD +0.34
Alkermes PLC $61.35 USD -0.45
BioMarin Pharmaceutical Inc $127.19 USD +0.31
Incyte Corp $107.69 USD -0.72
Sagent Pharmaceuticals Inc $22.57 USD -0.02
View Industry Companies
 

Industry Analysis

JAZZ

Industry Average

Valuation JAZZ Industry Range
Price/Earnings 52.6x
Price/Sales 9.0x
Price/Book 8.6x
Price/Cash Flow 32.7x
TEV/Sales 7.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit www.jazzpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.